ARCHIVES

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

This article is from The Cancer Letter archive.

Vol. 34 No. 4 | April 29, 2011

Download PDF Visit The Full Archive

Related Articles

Cancer Patient Lobby Outlines Agenda For FDA Reform, Seeks Role In Discussion

June 23, 1995

In Brief: David Harrington Replaces Zelen At ECOG; Kushnet To Receive Ewing Layman’s Award

December 1, 1989

NCAB Rejects Automatic Loss Of Comprehensive Status For Center Without Core Grants

September 29, 1978

NCI Eases Some Cooperative Group Concern; DeVita Considers Other CCOP- Research Base Funding Option

April 2, 1982

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

January 25, 2013

Bush Asks Hammer To Probe FDA Regulation Of Anticancer Drugs

June 17, 1988